Integer Holdings Corporation (ITGR) stock advanced more than 2% on Friday following the release of fourth-quarter 2025 earnings that exceeded expectations and prompted multiple analyst firms to raise their outlooks on the medical device manufacturer.
The company reported fourth-quarter sales of $472 million, representing 5% year-over-year growth, while non-GAAP net income increased 22% to $62 million for the period. The financial performance triggered rating and price target adjustments from three major research firms, including Benchmark, which initiated a buy rating with a $95 price target. Wells Fargo and Truist Securities also elevated their price targets on the stock, signaling increased confidence in the company's financial trajectory and operational execution.
The analyst upgrades reflect improved sentiment regarding Integer Holdings' business fundamentals and growth prospects in the competitive medical device sector. The coordinated positive revisions suggest broad-based analyst confidence in the company's ability to sustain profitability gains and drive shareholder value.